<div id="readability-page-1"><p>Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) have earned a consensus rating of &#34;Moderate Buy&#34; from the ten analysts that are currently  covering the company, Marketbeat reports. Two analysts have rated the stock with a sell rating, one  has given a hold rating, six have assigned  a buy rating and one  has issued  a strong buy rating on  the company. The average 12-month target price among analysts that have covered the stock in the last year is $51.5857.</p><ul><li>Zai Lab Stock Has Fallen to Value Levels </li></ul><p>Several equities analysts have recently issued reports on ZLAB shares. JPMorgan Chase &amp; Co. cut their price target on Zai Lab from $46.00 to $39.00 and set an &#34;overweight&#34; rating on the stock in a research note on Thursday, February 5th. Jefferies Financial Group upgraded shares of Zai Lab to a &#34;strong-buy&#34; rating in a research report on Monday, January 19th. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Zai Lab in a research note on Wednesday, January 21st. UBS Group started coverage on shares of Zai Lab in a research report on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $35.00 target price for the company. Finally, Zacks Research cut Zai Lab from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Friday, January 23rd.</p><p><b>Check Out Our Latest Stock Report on ZLAB</b></p><h2>Zai Lab Trading Up 2.4%</h2><p>ZLAB opened at $18.44 on Tuesday. Zai Lab has a 1-year low of $15.96 and a 1-year high of $44.34. The stock has a market capitalization of $2.06 billion, a PE ratio of -9.46 and a beta of 0.88. The firm has a 50-day moving average price of $18.08 and a two-hundred day moving average price of $25.88. </p><h2>Insiders Place Their Bets</h2><p>In related news, insider Rafael Amado sold 10,787 shares of the business's stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $17.43, for a total transaction of $188,017.41. Following the completion of the transaction, the insider owned 52,391 shares in the company, valued at approximately $913,175.13. The trade was a 17.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. 4.96% of the stock is owned by insiders. </p><h2>Institutional Trading of Zai Lab</h2><p>A hedge fund recently bought a new stake in Zai Lab stock. SG Americas Securities LLC bought a new stake in  Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 9,754 shares of the company's stock, valued at approximately $331,000. Institutional investors own  41.65% of the company's stock. </p><h2>Zai Lab Company Profile</h2> (Get Free Report)<p>Zai Lab Ltd <span>NASDAQ: ZLAB<span></span></span> is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&amp;D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.  </p><p>The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Zai Lab</li><li>The buying spree that no one is talking about</li><li>How to collect $500-$800 weekly (BlackRock's system)</li><li>Trump’s AI Secret: 100X Faster Than Nvidia</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>They just tried to kill gold</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WkxBQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WkxBQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zai Lab Right Now?</h2><p>Before you consider Zai Lab, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.</p><p>While Zai Lab currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) has received a consensus rating of "Moderate Buy" from ten analysts. The ratings include two sell, one hold, six buy, and one strong buy. The average 12-month target price is $51.59. Recent reports show mixed opinions, with JPMorgan lowering its target to $39 and Jefferies upgrading to strong buy. ZLAB shares opened at $18.44, with a market cap of $2.06 billion. Insiders own 4.96% of the stock, and institutional investors hold 41.65%.</p>

- Zai Lab Limited's shares have a consensus rating of "Moderate Buy" from ten analysts, with the average 12-month target price at $51.5857.  
- Recent analyst actions include JPMorgan reducing its price target from $46.00 to $39.00, while Jefferies upgraded the stock to "strong buy."  
- Zai Lab has a market capitalization of $2.06 billion and operates in biopharmaceuticals, focusing on innovative therapies.

Market Beat

Invesco Biotechnology & Genome ETF

China Merchants CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

Minsheng Royal CSI Biotechnology Theme ETF

SPDR S&P Biotech

Guotai CSI Bio-medicine ETF

ALPS Medical Breakthrough

Zai Lab

VanEck Biotech ETF

VG Health

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ChinaAMC CSI Biotechnology Theme ETF

ZAI LAB

E Fund CSI Biotechnology Theme ETF

Ark Genomic Revolution ETF

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Average Recommendation of "Moderate Buy" by Analysts